A decent end to FY24: investors jittery with biopharma headwinds
31/01/25 -"During FY24, Eurofins’ revenue was in line with market expectations, but the EPS and FCF outperformed. The initial knee-jerk reaction was attributable to continued weakness in the Biopharma ..."
Pages
47
Language
English
Published on
31/01/25
You may also be interested by these reports :
17/09/26
Just five weeks after reaffirming its outlook, Bilfinger cut FY26 adjusted EBITA guidance by 22%, reported EBITA by approximately 45% and free cash ...
27/08/26
The target price is unchanged as we make no material changes to our estimates or valuation. While organic growth is likely to remain subdued in H2 ...
12/08/26
Bilfinger’s Q2 revenue grew by 7% to €1.45bn and EBITA by 4% to €77m, both slightly ahead of expectations, but the underlying picture weakened. The ...
06/08/26
Q2 2026 confirmed solid revenue growth, driven by Adecco GBU’s strong performance across the Americas, Asia Pacific and most EMEA regions. While ...